EXAGEN INC. XGN
Nasdaq · XNAS · stock · Services-Medical Laboratories
Chart by TradingView
3/9
Piotroski F — financial health
-14.91
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $66.6M | -$20.0M | $38.8M | -$14.3M | $17.4M |
| 2024 | $55.6M | -$15.1M | $33.1M | -$13.8M | $9.5M |
| 2023 | $52.5M | -$23.7M | $29.5M | -$15.3M | $22.7M |
| 2022 | $45.6M | -$47.4M | — | -$36.5M | $42.5M |
| 2021 | $48.3M | -$26.9M | — | -$22.6M | $84.9M |
| 2020 | $42.0M | -$16.7M | — | -$14.5M | $41.8M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| ABALLI JOHN | President and CEO | 2026-03-12 | Grant | 150,000 | — |
| Black Jeffrey G. | Chief Financial Officer | 2026-03-12 | Grant | 75,000 | $3.16 |
| ABALLI JOHN | President and CEO | 2026-03-03 | Grant | 2,535 | $3.08 |
| ABALLI JOHN | President and CEO | 2026-03-03 | Sell | 15,698 | $3.62 |
| Black Jeffrey G. | Chief Financial Officer | 2026-02-27 | Grant | 1,511 | $3.08 |
| ABALLI JOHN | President and CEO | 2026-02-24 | Sell | 11,430 | $3.61 |
| Black Jeffrey G. | Chief Financial Officer | 2026-02-24 | Sell | 1,584 | $3.61 |
| ABALLI JOHN | President and CEO | 2025-10-16 | Sell | 31,787 | $11.82 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -14.91 (distress)
- Working capital / assets 0.599
- Retained earnings / assets -5.417
- EBIT / assets -0.242
- Equity / liabilities 0.43
Source: SEC EDGAR filings · CIK 0001274737 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.